+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Microbiome Therapeutics Market 2021-2025

  • ID: 5031157
  • Report
  • August 2021
  • Region: Global
  • 120 Pages
  • TechNavio
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the human microbiome therapeutics market and it is poised to grow by $516.08 mn during 2021-2025, progressing at a CAGR of 47.79% during the forecast period. The report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline.

The human microbiome therapeutics market analysis includes the application segment and geographic landscape.

The human microbiome therapeutics market is segmented as below:


By Application

  • Gastrointestinal disorders
  • Infectious diseases
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

The report on human microbiome therapeutics market covers the following areas:

  • Human microbiome therapeutics market sizing
  • Human microbiome therapeutics market forecast
  • Human microbiome therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc

Executive Summary

  • Market overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Gastrointestinal disorders - Market size and forecast 2020-2025
  • Infectious diseases - Market size and forecast 2020-2025
  • Others - Market size and forecast 2020-2025
  • Market opportunity by Application

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity By Geographical Landscape
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Application - Market share 2020-2025 (%)
22: Comparison by Application
23: Gastrointestinal disorders - Market size and forecast 2020-2025 ($ million)
24: Gastrointestinal disorders - Year-over-year growth 2020-2025 (%)
25: Infectious diseases - Market size and forecast 2020-2025 ($ million)
26: Infectious diseases - Year-over-year growth 2020-2025 (%)
27: Others - Market size and forecast 2020-2025 ($ million)
28: Others - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Application
30: Customer landscape
31: Market share By Geographical Landscape 2020-2025 (%)
32: Geographic comparison
33: North America - Market size and forecast 2020-2025 ($ million)
34: North America - Year-over-year growth 2020-2025 (%)
35: Europe - Market size and forecast 2020-2025 ($ million)
36: Europe - Year-over-year growth 2020-2025 (%)
37: Asia - Market size and forecast 2020-2025 ($ million)
38: Asia - Year-over-year growth 2020-2025 (%)
39: ROW - Market size and forecast 2020-2025 ($ million)
40: ROW - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity By Geographical Landscape ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: 4D pharma Plc - Overview
50: 4D pharma Plc - Product and service
51: 4D pharma Plc - Key offerings
52: 4D pharma Plc - Key customers
53: 4D pharma Plc - Segment focus
54: ENTEROME SA - Overview
55: ENTEROME SA - Product and service
56: ENTEROME SA - Key offerings
57: ENTEROME SA - Key customers
58: ENTEROME SA - Segment focus
59: Ferring B.V. - Overview
60: Ferring B.V. - Product and service
61: Ferring B.V. - Key offerings
62: Ferring B.V. - Key customers
63: Ferring B.V. - Segment focus
64: Johnson and Johnson Inc. - Overview
65: Johnson and Johnson Inc. - Business segments
66: Johnson and Johnson Inc. - Key offerings
67: Johnson and Johnson Inc. - Key customers
68: Johnson and Johnson Inc. - Segment focus
69: Kaleido Biosciences Inc. - Overview
70: Kaleido Biosciences Inc. - Product and service
71: Kaleido Biosciences Inc. - Key offerings
72: Kaleido Biosciences Inc. - Key customers
73: Kaleido Biosciences Inc. - Segment focus
74: OptiBiotix Health Plc - Overview
75: OptiBiotix Health Plc - Product and service
76: OptiBiotix Health Plc - Key offerings
77: OptiBiotix Health Plc - Key customers
78: OptiBiotix Health Plc - Segment focus
79: PureTech Health Plc - Overview
80: PureTech Health Plc - Business segments
81: PureTech Health Plc - Key offerings
82: PureTech Health Plc - Key customers
83: PureTech Health Plc - Segment focus
84: Second Genome Therapeutics - Overview
85: Second Genome Therapeutics - Product and service
86: Second Genome Therapeutics - Key offerings
87: Second Genome Therapeutics - Key customers
88: Second Genome Therapeutics - Segment focus
89: Seres Therapeutics Inc. - Overview
90: Seres Therapeutics Inc. - Product and service
91: Seres Therapeutics Inc. - Key offerings
92: Seres Therapeutics Inc. - Key customers
93: Seres Therapeutics Inc. - Segment focus
94: Takeda Pharmaceutical Co. Ltd. - Overview
95: Takeda Pharmaceutical Co. Ltd. - Product and service
96: Takeda Pharmaceutical Co. Ltd. - Key offerings
97: Takeda Pharmaceutical Co. Ltd. - Key customers
98: Takeda Pharmaceutical Co. Ltd. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
The publisher recognizes the following companies as the key players in the global human microbiome therapeutics market: 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd..

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is side effects of existing treatment.`

According to the report, one of the major drivers for this market is the growing prevalence of chronic diseases.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown